Research menu
Jump to menu

Publications:  Dr Tania Maffucci

Crescente M, Armstrong PC, Kirkby NS, Edin ML, Chan MV, Lih FB, Jiao J, Maffucci T et al.(2020). Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin. The FASEB Journal
Patel A, Garcia LF, Mannella V, Gammon L, Borg TM, Maffucci T, Scatolini M, Chiorino G et al.(2020). Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. Cancer research vol. 80, (12) 2676-2688.
Cisse O, Quraishi M, Gulluni F, Guffanti F, Mavrommati I, Suthanthirakumaran M, Oh LCR, Schlatter JN et al.(2019). Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth. J Exp Clin Cancer Res vol. 38, (1)
Mannella V, Bergamaschi D, Harwood C, Maffucci T (2019). Targeting selective phosphoinositide-3-kinase isoforms as a novel strategy in cutaneous squamous cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY. vol. 180, E213-E213.
Emmanouilidi A, Fyffe CA, Ferro R, Edling CE, Capone E, Sestito S, Rapposelli S, Lattanzio R et al.(2019). Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. J Exp Clin Cancer Res vol. 38, (1)
Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G et al.(2018). GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene vol. 37, (49) 6368-6382.
Arifin SA, Paternoster S, Carlessi R, Casari I, Ekberg JH, Maffucci T, Newsholme P, Rosenkilde MM et al.(2018). Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119. Biochim Biophys Acta vol. 1863, (9) 1132-1141.
Janus JM, O¿Shaughnessy RFL, Harwood CA, Maffucci T(2017). Phosphoinositide 3-kinase-dependent signalling pathways in cutaneous squamous cell carcinomas. Cancers vol. 9, (7)
Raimondi C, Calleja V, Ferro R, Fantin A, Riley AM, Potter BVL, Brennan CH, Maffucci T et al.(2016). A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion. Scientific Reports vol. 6, 26142-26142.
Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D et al.(2016). Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression. Oncotarget vol. 7, (14) 18325-18345.
Mavrommati I, Cisse O, Falasca M, Maffucci T(2016). Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. Scientific Reports vol. 6,
Maffucci T, Falasca M(2014). New insight into the intracellular roles of class II phosphoinositide 3-kinases. Biochem Soc Trans vol. 42, (5) 1378-1382.
Falasca M, Casari I, Maffucci T(2014). Cancer chemoprevention with nuts. J Natl Cancer Inst vol. 106, (9)
Edling CE, Selvaggi F, Ghonaim R, Maffucci T, Falasca M(2014). Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther vol. 15, (5) 524-532.
Franco I, Gulluni F, Campa CC, Costa C, Margaria JP, Ciraolo E, Martini M, Monteyne D et al.(2014). PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. Dev Cell vol. 28, (6) 647-658.
Maffucci T, Falasca M(2014). Analysis, regulation, and roles of endosomal phosphoinositides. Methods Enzymol vol. 535, 75-91.
Mazza S, Maffucci T(2014). Autophagy and pancreatic β-cells. Vitam Horm vol. 95, 145-164.
Falasca M, Maffucci T(2014). Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol vol. 5,
Mazza S, Maffucci T, Falasca M(2013). Investigating the mechanisms of activation and action of phosphoinositide 3-kinase C2 alpha in pancreatic beta cells. DIABETIC MEDICINE vol. 30, 32-32.
Tibolla G, Piñeiro R, Chiozzotto D, Mavrommati I, Wheeler AP, Norata GD, Catapano AL, Maffucci T et al.(2013). Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. PLoS One vol. 8, (1)
Raimondi C, Chikh A, Wheeler AP, Maffucci T, Falasca M(2012). A novel regulatory mechanism links PLCγ1 to PDK1. J Cell Sci vol. 125, (Pt 13) 3153-3163.
Falasca M, Maffucci T(2012). Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem J vol. 443, (3) 587-601.
Maffucci T(2012). An introduction to phosphoinositides. Curr Top Microbiol Immunol vol. 362, 1-42.
Mavrommati I, Maffucci T(2011). mTOR Inhibitors: Facing New Challenges Ahead. Curr Med Chem
Dominguez V, Raimondi C, Somanath S, Bugliani M, Loder MK, Edling CE, Divecha N, da Silva-Xavier G et al.(2011). Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. J Biol Chem vol. 286, (6) 4216-4225.
Piñeiro R, Maffucci T, Falasca M(2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene vol. 30, (2) 142-152.
Falasca M, Raimondi C, Maffucci T(2011). Boyden chamber. Methods Mol Biol vol. 769, 87-95.
Mazza S, Maffucci T(2011). Class II phosphoinositide 3-kinase C2alpha: what we learned so far. Int J Biochem Mol Biol vol. 2, (2) 168-182.
Mavrommati I, Maffucci T(2011). mTOR inhibitors: facing new challenges ahead. Curr Med Chem vol. 18, (18) 2743-2762.
Edling CE, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, Innocenti P, Kocher HM et al.(2010). Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res vol. 16, (20) 4928-4937.
Persaud SJ, Arden C, Bergsten P, Bone AJ, Brown J, Dunmore S, Harrison M, Hauge-Evans A et al. (2010). Pseudoislets as primary islet replacements for research. Islets report no. Islets 2(4),
Persaud SJ, Arden C, Bergsten P, Bone AJ, Brown J, Dunmore S, Harrison M, Hauge-Evans A et al.(2010). Pseudoislets as primary islet replacements for research: report on a symposium at King's College London, London UK. Islets vol. 2, (4) 236-239.
Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BVL, Broggini M et al.(2010). A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer vol. 102, (1) 104-114.
Raimondi C, Maffucci T, Potter BVI, Falasca M (2010). A novel and selective PDK1 inhibitor reduces breast cancer cell invasion and tumour growth. BREAST CANCER RESEARCH. vol. 12, S3-S3.
Abbott J, Pineiro R, Oliviero MA, Lattanzio R, Piantelli M, Bilancio A, Maffucci T, Falasca M (2010). Phosphoinositide 3-kinase class II beta is a novel target in breast cancer therapy. BREAST CANCER RESEARCH. vol. 12, S5-S5.
Maffucci T, Raimondi C, Abu-Hayyeh S, Dominguez V, Sala G, Zachary I, Falasca M(2009). A phosphoinositide 3-kinase/phospholipase Cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation. PLoS One vol. 4, (12)
Falasca M, Maffucci T(2009). Rethinking phosphatidylinositol 3-monophosphate. Biochim Biophys Acta vol. 1793, (12) 1795-1803.
Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M et al.(2008). Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res vol. 68, (24) 10187-10196.
Falasca M, Hughes WE, Dominguez V, Sala G, Fostira F, Fang MQ, Cazzolli R, Shepherd PR et al.(2007). The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem vol. 282, (38) 28226-28236.
Falasca M, MAFFUCCI T, Fostira F, Sala G, Dominguez V, Hughes WE, James DE, Fang MQ et al.(2007). The role of phosphoinositide 3-kinase C2alpha in insulin signaling. Journal of Biological Chemistry vol. 282, (38) 28226-28236.
Maffucci T, Falasca M (2007). Phosphoinositide 3-kinase-dependent regulation of phospholipase Cgamma. Biochem Soc Trans. vol. 35, 229-230.
Falasca M, Maffucci T (2007). Role of class II phosphoinositide 3-kinase in cell signalling. Biochem Soc Trans. vol. 35, 211-214.
Falasca M, Maffucci T(2006). Emerging roles of phosphatidylinositol 3-monophosphate as a dynamic lipid second messenger. Arch Physiol Biochem vol. 112, (4-5) 274-284.
Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C et al.(2005). Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res vol. 65, (18) 8339-8349.
Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, Falasca M(2005). Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol vol. 169, (5) 789-799.
(2004). 40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004. Diabetologia vol. 47, (Suppl 1) A1-A464.
Falasca M, Maffucci T (2004). Phosphatidylinositol-3-phosphate, a new crucial player in insulin signalling, is generated via a TC10-mediated phosphoinositide 3-kinase C2alpha activation. DIABETOLOGIA. vol. 47, A68-A69.
Piccolo E, Vignati S, Maffucci T, Innominato PF, Riley AM, Potter BVL, Pandolfi PP, Broggini M et al.(2004). Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene vol. 23, (9) 1754-1765.
Maffucci T, Brancaccio A, Piccolo E, Stein RC, Falasca M(2003). Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J vol. 22, (16) 4178-4189.
Maffucci T, Razzini G, Ingrosso A, Chen H, Iacobelli S, Sciacchitano S, Quon MJ, Falasca M(2003). Role of pleckstrin homology domain in regulating membrane targeting and metabolic function of insulin receptor substrate 3. Mol Endocrinol vol. 17, (8) 1568-1579.
Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S, Falasca M(2002). The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene vol. 21, (42) 6520-6529.
Marra P, Maffucci T, Daniele T, Tullio GD, Ikehara Y, Chan EK, Luini A, Beznoussenko G et al.(2001). The GM130 and GRASP65 Golgi proteins cycle through and define a subdomain of the intermediate compartment. Nat Cell Biol vol. 3, (12) 1101-1113.
Marra P, Maffucci T, Daniele T, Di Tullio G, Ikehara Y, Chan EKL, Luini A, Mironov A et al.(2001). The Golgi matrix proteins GM130 and GRASP65 cycle through a novel subdomain of the intermediate compartment. MOL BIOL CELL vol. 12, 208A-208A.
Innominato PF, Mariggio' MA, Piccolo E, Maffucci T, Iacobelli S, Falasca M(2001). The mechanism involved in the regulation of PLC gamma 1 activity in cell migration. CLIN CANCER RES vol. 7, (11) 3780S-3780S.
Maffucci T, Falasca M(2001). Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide-protein co-operative mechanism. FEBS Lett vol. 506, (3) 173-179.
Return to top